A401of which were hysterectomies. Before the launch of UPA in France, number of surgeries increased by 380 each year. The introduction of UPA was correlated with a trend reversal, showing a decrease in the number of surgeries of 1,236 each year from mid-2013. UPA did not have an impact on the type of surgery, neither on the surgical approach. The savings associated with the use of UPA pre-operatively (cost of treatment and avoided surgeries included) were estimated at 2M€ in 2013 and will reach 9M€ in 2016, that was considered as a plateau for the following years. The cumulated budgetary impact from 2016 to 2019 is estimated at -37M€ . ConClusions: Thanks to avoided surgeries, the use of UPA as pre-operative treatment is associated with financial savings, which cover largely the treatment costs. PIH10 Budget-ImPact analysIs (BIa) Of tHe IntrOductIOn Of 52mg levOnOrgestrel-releasIng IntrauterIne system (lng-Ius) as a cOntracePtIve metHOd OPtIOn In tHe BrazIlIan PuBlIc HealtHcare system (sus) tO avOId unIntended Pregnancy (uP) In 15 tO 19 year-Old adOlescents

The study was a retrospective analysis of DataSUS, a Brazilian Public Health System medical claims database. Patients were tracked by the ICD between July 2011 and June 2016. The disease costs were segmented between diagnostic and treatment costs, for each disease status, according to SUS list of procedures. The total costs of HCC were calculated by multiplying the mean annual frequency per patient of each performed procedure at each stage of the disease by its cost and added to the cost of the diagnostic procedures performed in the respective year. The costs were also projected for the next 5 years. Costs expressed in 2016 prices, exchange rate 1.00 USD = 3.19 BRL. ReSultS: 28,822 patients were identified. 11% of the sample was on initial stage, 13% on intermediate, 9% on advanced and 67% were already diagnosed on terminal stages, receiving only palliative care. In 2016, the costs for treating HCC were USD 7.6 million for 9,028 patients, reaching USD 8.7 million for 10,042 patients in 2021. The stage with the greatest economic impact was the intermediate, with average annual costs estimated at USD 3.04 million, followed by the advanced stage, with an average annual cost of USD 2.33 million. Regarding the economic impact per patient, the advanced stage had the higher costs (USD 2,821). cOncluSiOnS: More than 75% of the patients are already diagnosed in late stages, where there are no more curative treatment options, and 67% are already diagnosed in the terminal stage of the disease. Thus, the development of screening strategies for patients with hepatopathies and early diagnosis are essential to increase the number of patients diagnosed under curative conditions, where there may be optimization of health resources.

137) of the cases returned negative results, 32% (44) of these patients were irrationally prescribed with anti-malarial drugs sans confirmed diagnosis with injectable artesunate (61%) and chloroquine (32%) for an average of 4 days resulting in 41% overdoses and 38% under doses. Direct cost associated was estimated to be USD 1,167.71. Female bedridden patients with fever and chills ≤ 3 days with normal hematological parameters, liver and renal function tests were more likely prescribed with anti-malarials. These patients had fewer co-morbidities, lower mortality, longer survival rate and longer hospitalization (p< 0.05). ConClusions: Through geriatric pharmaceutical care services, clinical pharmacist can reduce inappropriate prescribing and prevent possible adverse effects without hampering the health related quality of life.